Skip to content
Peptigraph home

Semaglutide for Depression: What the Evidence Shows

What human and animal studies show about Semaglutide for depression, how strong that evidence is, and what is still unproven.

Medically reviewed by Juan Pablo Frías, MD · · DisclosureGLP-1 agonistUpdated
Strongest evidence
Human observational
Human studies
2
with an outcome for depression, in our evidence file (PubMed search, 2 Oct 2026)
Animal studies
None found
with an outcome for depression, in our evidence file (PubMed search, 2 Oct 2026)
Studies we summarised
2
with an outcome for depression

Evidence for depression

Each row is an outcome related to depression from a published study, strongest design first. Animal and cell results are labelled and are not human results. User reports are not counted as evidence here.

Semaglutide for depression: outcomes in published studies
OutcomeResultStudy typeSource
Neuropsychiatric safetySemaglutide was not associated with higher 12-month risk of adverse neuropsychiatric outcomes versus other antidiabetic drugs.Human observationalEClinicalMedicine 2024, PMID 39764175
Depression, anxiety and suicidal behaviorThis cohort study found 195% higher risk of major depression, 108% higher risk of anxiety and 106% higher risk of suicidal behavior in patients on GLP-1 RAs; observational and conflicts with other cohort data.Human observationaln = 162253Scientific reports 2024, PMID 39424950

Semaglutide and depression are not in our PubMed count ledger yet; the rows above come from our evidence file (PubMed search, 2 Oct 2026). Grades follow our .

How strong is it?

Strongest evidence:Human observational evidence, 3 of 4EClinicalMedicine 2024, PMID 39764175

A human randomized trial outweighs any number of animal studies. Animal and cell results show a mechanism worth testing, not that it works in people.

What depression is, and what has been studied

MedlinePlus describes depression as a serious mood disorder, not just a few days of feeling sad or irritable.[3]

We found no randomised trial of semaglutide for depression. The evidence is observational, and the cohorts point in different directions.[1]

Two cohorts that disagree

A matched cohort of people with type 2 diabetes found no excess of neuropsychiatric outcomes, including depression and suicidality, after semaglutide compared with other diabetes drugs.[1]

A different cohort reported that patients on GLP-1 drugs had a 195% higher risk of major depression, 108% higher for anxiety and 106% higher for suicidal behaviour.[2]

A review of real-world studies found no clear increase in depression and self-harm among GLP-1 users, so the cohort signals do not agree.[4]

Wegovy and depression: what the label says now

The Wegovy label's revision history lists its suicidal behaviour and ideation warning as removed.[5]

Other peptides people research for depression

All peptides for depression, compared

Common questions

Does Semaglutide help with depression?

The strongest study we summarise for depression is human observational evidence, across 2 studies with an outcome for depression. That is not proof it works in people.

Is Semaglutide approved for depression?

Semaglutide is FDA approved (Ozempic, Wegovy, Rybelsus). Which conditions that approval covers is set by the label; use for anything else is off-label.

What is the best peptide for depression?

There is no single answer. Our depression overview compares each candidate by evidence grade and legal status rather than by popularity.

Does semaglutide cause depression?

The evidence conflicts: one cohort reported a much higher recorded risk of major depression among GLP-1 users, another found no excess, and neither is a randomised trial.[2]

Can semaglutide treat depression?

We found no trial of semaglutide for depression. A review describes only preliminary indications of benefit from GLP-1 drugs in some conditions.[6]

Does Rybelsus cause depression?

Rybelsus's warnings and precautions highlights name pancreatitis, retinopathy, low blood sugar with insulin, kidney injury, severe GI reactions, hypersensitivity, gallbladder disease and aspiration under anesthesia. Depression is not among them. The thyroid tumor warning is boxed separately, and the cohort studies above still disagree.[7]

More on Semaglutide

Sources

  1. 112-month neurological and psychiatric outcomes of semaglutide use for type 2 diabetes: a propensity-score matched cohort study.EClinicalMedicine · 2024PMID 39764175Accessed 2 Oct 2026
  2. 2The risk of depression, anxiety, and suicidal behavior in patients with obesity on glucagon like peptide-1 receptor agonist therapy.Scientific reports · 2024PMID 39424950Accessed 2 Oct 2026
  3. 3Official web pageOfficial web page · web page
  4. 4Real-world evidence on the utilization, clinical and comparative effectiveness, and adverse effects of newer GLP-1RA-based weight-loss therapies.Diabetes, obesity & metabolism · 2025PMID 40196933Accessed 2 Oct 2026
  5. 5WEGOVY prescribing information (FDA label)FDA label, DailyMed · current labeldailymed.nlm.nih.govAccessed 2 Oct 2026
  6. 6[Glucagon-like peptide-1 receptor agonists: a new pharmacological treatment option for psychiatric illnesses?].Der Nervenarzt · 2025PMID 40042613Accessed 2 Oct 2026
  7. 7RYBELSUS and OZEMPIC tablets prescribing information (FDA label)FDA label, DailyMed · current labeldailymed.nlm.nih.govAccessed 2 Oct 2026

Found an error? Report a correction.